539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

M.J.Hawkins; J.R.Lane; L.Harris; P.J.Williams; V.Trieu; P.Soon-Shiong; N.Desai

首页> 外文期刊>European Journal of Cancer Supplements >539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

【24h】

539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

机译：539对晚期实体瘤患者中无cremophor，蛋白质稳定的纳米颗粒制剂（ABI-007）和基于cremophor的紫杉醇（P）进行比较药代动力学（PK）研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第8期|共1页
作者
M.J.Hawkins; J.R.Lane; L.Harris; P.J.Williams; V.Trieu; P.Soon-Shiong; N.Desai;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. [J] . Nyman DW, Campbell KJ, Hersh E, Journal of Clinical Oncology . 2005,第31期

机译：ABI-007（紫杉醇的一种新型纳米颗粒制剂）用于晚期非血液系统恶性肿瘤患者的I期和药代动力学试验。
2. 1495 PUBLICATION Pharmacokinetics (PK) of AMG 706 on CYP3A activity using oral midazolam and the bioavailability of solid formulations in patients (pts) with advanced solid tumors: results of two phase 1 substudies [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1495年发表的AMG 706对口服咪达唑仑的CYP3A活性的药代动力学（PK）和固体制剂在晚期实体瘤患者中的生物利用度：两项1期亚项研究的结果
3. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies [J] . Meiqi Shi, Jing Sun, Jinsong Zhou, Investigational new drugs. . 2018,第2期

机译：高级实体恶性肿瘤患者聚合物胶束紫杉醇纳米粒子制剂的纳米粒子制剂的I相剂量升级和药代动力学研究
4. PD/PK Characterization of Drug Release From Nanoparticles Independent of Formulation: Acute Pharmacokinetics and Cardiovascular Effects of Intravenous Nifedipine [C] . Vrbanac JJ, Humphrey SJ, Buhl AE, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：纳米颗粒的Pd / PK表征药物释放独立于制剂：静脉注射氮素的急性药代动力学和心血管作用
5. Formulation, Characterization and Evaluation of Paclitaxel loaded Solid Lipid Nanoparticles Prepared by Temperature Modulated Solidification Technique. [D] . Deshpande, Ameya Abhay. 2015

机译：通过温度调制固化技术制备的负载紫杉醇的固体脂质纳米颗粒的制备，表征和评价。
6. Phase I and Pharmacokinetic Study of ABI-007 Albumin-bound Paclitaxel Administered Every 3 Weeks in Japanese Patients with Solid Tumors [O] . Kazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, -1

机译：日本实体瘤患者每3周进行ABI-007（与白蛋白结合的紫杉醇）的I期和药代动力学研究
7. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. [O] . Neil Desai, Vuong Trieu, Zhiwen Yao, 2006

机译：与Cremophor为基础的紫杉醇相比，增加抗肿瘤活性，腹腔紫杉醇浓度和Remophor的无白蛋白结合的紫杉醇Abi-007的内皮细胞传输。

539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

著录项

相似文献

相关主题

期刊订阅